18:39 , Jan 18, 2018 |  BC Innovations  |  Emerging Company Profile

Allogeneic expansion

Rather than taking the conventional approach of starting with autologous therapies, Adicet Bio Inc. is building an allogeneic pipeline from the get-go as part of the charge to make γδ T cells for solid and...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Applied Immune Technologies, Adicet deal

Adicet acquired Applied Immune Technologies, which develops T cell receptor-like antibodies for therapeutic and diagnostic applications in cancer, inflammation, autoimmune and infectious diseases. Adicet is a preclinical-stage biotech developing cancer immunotherapies. The companies declined to...
02:24 , Jan 28, 2016 |  BC Extra  |  Financial News

Adicet raises $51 million series A

Adicet Bio Inc. (Menlo Park, Calif.) raised $51 million in a series A round led by OrbiMed. Other investors included Novartis Venture Fund and Pontifax. Adicet said it is developing preclinical universal immune cell therapies...